Hangzhou, China / July 22, 2025-AusperBio (Ausper Biopharma Co.，Ltd.AndAusperBio Therapeutics Inc.), an innovative drug research and development company in the clinical stage, focuses on developing self-innovative targeted delivery small nucleic acid drugs and is committed to achieving the goal of clinically curing chronic hepatitis B. The company announced today that the Center for Drug Evaluation of the China National Medical Products Administration (CDE) has approved its core candidate drug AHB-137 LaunchIIIPhase clinical trial.

This timeIIIThe Phase III clinical trial is a randomized, double-blind, multi-center study conducted in China, aiming to evaluate the treatment over a period of... 24 Week, Dose 300 mg TheAHB-137 Receiving stable nucleos(t)ide analog treatment HBeAg Efficacy and Safety in Patients with Negative Chronic Hepatitis B.

Chronic Hepatitis B (CHB) is a major global public health issue, with approximately2.9 Million, of which about China 7,500 Millions, which can subsequently lead to severe complications such as liver cirrhosis and hepatocellular carcinoma. Although existing therapies can suppress viral replication, the vast majority of patients still struggle to achieve clinical cure.

AHB-137It is a non-conjugated antisense oligonucleotide with the potential to become a cornerstone for clinical cure of chronic hepatitis B.ASO) drug, and has received widespread attention and recognition for its significantly outstanding efficacy and safety.

• 2024Year 7 Month  ，AHB-137In China CDE Approved, included in the breakthrough therapy category;

• 2024 Year 11 Month  ，AHB-137 Clinical IIaData Research Results from the Treatment Period Selected for the Annual Meeting of the North American Society for the Study of Liver Diseases (AASLD™) and released as the latest breakthrough results in an oral report;

•  2025 Year 3 Month   AHB-137 Clinical IIaKey Data Research Results of the Period Selected for the Annual Conference of the Asian Liver Disease Society (APASL™) and released as the latest breakthrough results in an oral report;

•  2025 Year 5 Month   ，AHB-137 ClinicalIIbEnd-of-Treatment Data from Phase Clinical Trial Selected for Annual Meeting of the European Association for the Study of the Liver (EASL™) and released the results in a breakthrough poster format.

  
  

Co-founder andCEODr. Guofeng ChengRepresents: "ChinaCDEApprovalAHB-137Official Launch III The Phase clinical trial, receiving this notice has greatly inspired us. Following last year's acquisition of the Breakthrough Therapy Designation, this approval once again strongly confirms AHB-137 The outstanding efficacy and safety demonstrated in previous clinical studies have further strengthened our confidence inAHB-137Become the cornerstone drug for clinical cure of chronic hepatitis B with confidence. This is not only AusperBio An important leap in the development process, as well as the entire Hepatitis B virus (HBV) A milestone in the development of clinical cure."

AusperBio Co-Founder andCSODr. Chengyong YangSaid: "AusperBio This significant milestone could not have been achieved without the selfless dedication of researchers, clinical teams, trial participants, and our hardworking colleagues. We extend our heartfelt thanks to them. We will initiate this pivotal clinical trial as soon as possible, aiming to bring a transformative treatment option to patients with chronic hepatitis B worldwide at the earliest opportunity.”

This time III The approval of the clinical trial is AusperBio A Key Step Toward Achieving the Clinical Cure of Chronic Hepatitis B. A science-based, patient-centered R&D pathway not only drives a paradigm shift in hepatitis B treatment from "control" to "cure," but also injects innovative momentum into the global drug development field.

AboutAusperBio：AusperBioAusperBioIs a clinical-stage innovative drug research and development company operating synchronously in China and the United States, dedicated to researching and developingFirst-in-classAndBest-in-classSelf-innovated targeted delivery small nucleic acid drugs. AusperBio owns independent intellectual property rights.Med-Oligo™ ASO Patent Technology Platform, Focusing onHBVFunctional Cure for Chronic Hepatitis B and Highly Targeted Treatments for Liver Diseases, Expanding to Targeted Small Nucleic Acid Therapies for New Targets Beyond the Liver. AusperBio's strategy is to leverage its internationally leadingMed-Oligo™ Oligonucleotide technology combined with specific and efficient targeting technology to address a wide range of currently unmet medical needs.

AboutAHB-137：AHB-137Is a non-conjugated antisense oligonucleotide with the potential to become a cornerstone for clinical cure of chronic hepatitis B (ASO), is an independently developed platform by AusperBio.Med-Oligo™The first innovative drug to enter clinical trials, with excellent preclinical and clinical data presented at the European Liver Conference (EASL™ 2023,2024,2025) and2024Annual AASLD Conference (AASLD™) has gained widespread attention. Currently,AHB-137An international multicenterIPhase clinical trials and multiple trials conducted in ChinaIIPhase clinical trials. Through global layout, accelerate the goal of achieving clinical cure for hepatitis B.

About

Sherpa Investment

Sherpa Investment is a fund management company focused on early and growth-stage healthcare investments. WeAdhere to the concept of "investing early, investing in innovation, and investing accurately."Based on the long-term accumulated industry knowledge and advantageous resources,Targeting the unmet rigid clinical needs in the field of major diseases, we build an investment portfolio around sectors such as gene technology and its applications, biopharmaceuticals, device diagnostics, and digital healthcare. We expand along the depth of the industry and its upstream and downstream to form corporate synergies, with investment presence in both China and the United States.

The Sherpa team, with both industry and investment backgrounds, supports critical decision-making at key stages of enterprise development by actively sharing operational management experience and providing a forward-looking perspective across the entire industrial chain, helping companies achieve growth in business performance and corporate value.Ten years of honing a single sword, long-term professional focus, and accumulated learning have built the Sherpa Investment brand and established a comprehensive capability system covering project sourcing, post-investment value-added services, exits, and more.

The medical enterprises invested in and led by Sherpa team members include Innovent Biologics, New Horizon Health, Belief BioMed, Berry Genomics, NanoView Biosciences, Singleron Biotechnologies, NorthX Biologics, Wuxi AppTec, WuXi Biologics, Cytek Biosciences, Axonics, Urotronic, Visen Pharmaceuticals, Avida Biomed, Alamar Biosciences, Bota Bio, Vazyme Biotech, OBiO Technology, Heartcare Medical, Olive Branch Health, Jianhai Technology, Mabcomm, and more than a hundred other companies.

Adhering to the values of "investing in health, achieving others and oneself," the Sherpa team is honored to join hands with many outstanding entrepreneurs. Through innovative technologies and products, we benefit human health, participate in and witness the growth of China's medical industry together, and strive to become the most trusted Sherpa for entrepreneurs who are scaling the peak of life sciences.

Invest in Health, Achieve for Others and Yourself
Be Great，Make Others Great